Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Tumour Biol ; 28(2): 63-9, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17264538

RESUMO

AIM: Our purpose was to determine whether S-100B or melanoma inhibitory activity (MIA) concentrations in the serum of patients with large uveal melanomas were better markers for the presentation of metastases than liver function tests. We also investigated whether increased marker levels were related to known clinical and histopathological prognostic parameters. METHODS: Total S-100B (A1B + BB) and MIA concentrations were measured in the sera from 104 patients with uveal melanoma prior to enucleation and in the sera from 50 healthy controls. Concentrations were also determined in the sera from 30 patients with known uveal melanoma metastases. Liaison Sangtec 100, an automated immunoluminometric assay measuring the total S-100B, and Roche MIA ELISA were used to quantify these proteins in serum. Results were compared with liver function tests [alkaline phosphatase, lactate dehydrogenase (LD), aspartate aminotransferase, alanine aminotransferase and gamma-glutamyl transpeptidase]. RESULTS: The mean S-100B and MIA concentrations were significantly higher in patients with metastases compared to melanoma patients without metastases. At the time of enucleation, S-100B and MIA were not prognostic for metastases in uveal melanoma, but S-100B and LD were the best tests to predict the occurrence of metastatic disease during the follow-up period. CONCLUSIONS: In our study, the S-100B and MIA serum concentrations were not correlated with any tested established prognostic parameter. S-100B and LD showed better performance in identifying melanoma metastases than gamma-glutamyl transpeptidase and MIA. A prospective follow-up study is needed to evaluate S-100B and MIA in identifying early micrometastasis in uveal melanoma.


Assuntos
Biomarcadores Tumorais/sangue , Proteínas da Matriz Extracelular/sangue , Testes de Função Hepática , Melanoma/sangue , Proteínas de Neoplasias/sangue , Fatores de Crescimento Neural/sangue , Proteínas S100/sangue , Neoplasias Uveais/sangue , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Melanoma/secundário , Prognóstico , Subunidade beta da Proteína Ligante de Cálcio S100 , Neoplasias Cutâneas/sangue , Neoplasias Cutâneas/secundário , Neoplasias Uveais/patologia , gama-Glutamiltransferase/sangue
3.
Invest Ophthalmol Vis Sci ; 41(13): 4074-9, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11095598

RESUMO

PURPOSE: World Health Organization guidelines for antibiotic treatment of trachoma currently include a 6-week course of tetracycline eye ointment twice daily or a single dose of oral azithromycin. Previous trials have shown similar efficacy of these two alternatives when administration of the ointment was carefully supervised. It is believed, however, that azithromycin may be a more effective treatment in practice, and the purpose of this study was to test that hypothesis. METHODS: A masked randomized controlled trial was conducted to compare azithromycin and tetracycline under practical operational conditions-i.e., without supervision of the administration of the ointment. Three hundred fourteen children aged 6 months to 10 years with clinically active trachoma were recruited and individually randomized to receive one of the two treatments. Follow-up visits were conducted at 10 weeks and 6 months. The outcome was resolution of disease (clinical "cure"). RESULTS: Children allocated to azithromycin were significantly more likely to have resolved disease than those allocated to tetracycline, both at 10 weeks (68% versus 51%; cure rate ratio, 1.31; 95% confidence interval [CI], 1.08-1.59; P = 0.007) and at 6 months (88% versus 73%; cure rate ratio, 1.19; 95% CI, 1.06-1.34; P = 0.004). Azithromycin was particularly effective for intense inflammation (P = 0.023, Fisher's exact test). CONCLUSIONS: Single-dose oral azithromycin was a more effective treatment for active trachoma than tetracycline ointment as applied by caregivers. The high cure rate achieved with tetracycline in this study in the absence of supervision and the significantly higher costs of azithromycin, suggest that in the absence of donation programs, switching routine treatment from tetracycline to azithromycin would not be a good use of resources.


Assuntos
Antibacterianos/administração & dosagem , Azitromicina/administração & dosagem , Tetraciclina/administração & dosagem , Tracoma/tratamento farmacológico , Administração Tópica , Cuidadores , Criança , Pré-Escolar , Método Duplo-Cego , Feminino , Gâmbia/epidemiologia , Humanos , Lactente , Masculino , Pomadas , Prevalência , Tracoma/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA